Drug Type TIL therapy |
Synonyms- |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 01 Jan 2021 | |
Brain Cancer | Phase 1 | CN | 01 Jan 2021 | |
Breast Cancer | Phase 1 | CN | 01 Jan 2021 | |
Colorectal Cancer | Phase 1 | CN | 01 Jan 2021 | |
Liver Cancer | Phase 1 | CN | 01 Jan 2021 | |
Lung Cancer | Phase 1 | CN | 01 Jan 2021 |